Imatron Announces EBT Scanner Sale to BroMenn Healthcare in Bloomington,
Illinois; Represents Record 9th EBT Scanner
Sale in Third Quarter
Business Editors & High-Tech/Medical Writers
SO. SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sept. 26, 2000--
Imatron Inc. (Nasdaq:IMAT) announced today that it has sold an
Electron Beam Tomography (EBT) scanner to BroMenn Healthcare in
Bloomington-Normal, Illinois. This sale will be recorded in the
Company's third quarter financial results and represents the ninth EBT
scanner sale to date during the quarter.
BroMenn Healthcare will offer coronary artery scanning services
utilizing Imatron's EBT scanner to McLean and the surrounding Illinois
counties. The facility is anticipated to be operational in early
November of this year.
Shirley Weller, BroMenn Cardiology Services Coordinator, stated,
"BroMenn looks forward to enhancing our cardiac health improvement
initiatives with the addition of EBT. We will now be able to detect
the presence of calcium in the coronary arteries thereby diagnosing
the presence and extent of atherosclerosis in an individual patient.
This service, when added to the Heart Care First Cardiac Wellness
Program and Dr. Dean Ornish Program for Reversing Heart Disease,
expands the unique and comprehensive cardiovascular disease diagnosis
and prevention resources available for the communities we serve."
S. Lewis Meyer, Imatron's CEO, stated, "This sale to BroMenn
Healthcare represents another significant and continuing step in the
recognition by the healthcare community of the power of Imatron's EBT
technology as the cornerstone of programs focused on the prevention of
cardiovascular disease. We are now seeing a wide range of heart
disease preventative strategies centered around our EBT scanner being
implemented all across the country. We are confident that this growing
awareness of the efficacy of preventing disease at the earliest, most
curable stages rather than waiting for the manifestation of obvious
and serious symptoms will continue to build momentum for increasing
Imatron's sales revenues and profits. With seven scanner sales in the
first quarter, eight in the second, and now nine EBT scanner sales in
the third quarter, Imatron's sales are clearly accelerating in
response to growing demand for the unique diagnostic information
provided by our EBT scanner."
For additional information about Imatron, visit the Company's web
site at www.imatron.com.
Imatron Inc. is primarily engaged in designing, manufacturing,
marketing, and supporting high performance electron beam tomography
(EBT) scanners based on the Company's proprietary EBT technology.
Imatron's EBT scanner is now in use at more than 130 major medical
facilities and imaging centers around the world, including the Mayo
Clinic, Cedars-Sinai Medical Center, Abbott-Northwestern Hospital,
Mount Sinai Medical Center, University of Iowa, National Institutes of
Health, UCLA Medical Center, St. Francis Hospital, Stanford
University, University of Pittsburgh Medical Center, Edward
Cardiovascular Institute, Michigan Heart Imaging, Ohio Heart,
University of Illinois, Arizona Heart Institute, Alfried Krupp
Krankenhaus, Essen, Landeskrankenhaus in Graz, Austria, Cardiology
Research Centre in Moscow, Russia, FAU Erlangen-Nurnberg in Erlangen,
Germany, Beijing Hospital in China, HeartScan Imaging, Cooper Clinic,
HealthScan of La Jolla, LifeScore of San Diego and HealthScan of Plano
(Dallas).
Except for the historical information contained herein, the
matters discussed in this news release may contain forward-looking
statements that are based on current expectations and estimates about
the industry in which Imatron operates, the estimated impact of
certain technological advances, the estimated impact of published
research studies on scanner sales and procedures, as well as
management's beliefs and assumptions. It is important to note that the
Company's actual results could differ materially from those projected
in such forward-looking statements. The factors that could cause
actual results to differ materially include, among others; failed
clinical demonstration of certain asserted technological advantages
and diagnostic capabilities; reliance on product distributors;
competition in the diagnostic imaging market; failure to improve
product reliability or introduce new product models and enhancements;
delays in production and difficulty in obtaining components and
sub-assemblies from limited sources of supply; inability to meet
cash-on-delivery or prepayment terms from vendors; determinations by
regulatory and administrative government authorities; patent
expiration and denial of patent applications; the high cost of the
scanner as compared to commercially available CT scanners; and the
risk factors listed from time to time in the Company's Securities and
Exchange Commission reports, including their reports of Form 10-K for
their current fiscal year.
--30--lr/sf* mc/sf
CONTACT: Imatron, Inc., So. San Francisco
S. Lewis Meyer, 650/583-9964 (CEO)
Robin Kelley, 650/583-9964 (Investor Relations)
KEYWORD: CALIFORNIA ILLINOIS
INDUSTRY KEYWORD: COMPUTERS/ELECTRONICS MEDICAL MEDICAL DEVICES
HARDWARE PRODUCT MARKETING AGREEMENTS
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
Sep-26-2000 12:36 GMT
Symbols:
US;IMAT CA;IMAT
Source BW Business Wire |
